Gov't Pledges Fair Compensation as Process Begins to Acquire 600 Acres in Matugga for Dei BioPharma Expansion
MATUGGA, UGANDA — The Ugandan government has officially initiated the process to secure 600 acres of land in Matugga, Wakiso District, to facilitate the major expansion of Dei BioPharma Limited.
During a community meeting with residents of Gombe Division in Nansana Municipality, government officials reassured the public that the land acquisition will strictly follow constitutional guidelines. The meeting followed a directive by President Yoweri Museveni to resettle families living around the pharmaceutical campus, driven by international regulatory standards that require strict buffer zones between manufacturing plants and residential areas.
Key Details of the Acquisition
• Affected Areas: Technical teams and Lands Ministry experts will begin community sensitisation and demarcation in Wabitembe, Kiryowa, and Kigoogwa villages.
• Direct Process: Lands Minister Judith Nabakooba emphasized that the valuation and compensation will be handled directly by the government and landowners, warning residents to avoid third-party intermediaries.
• Fair Compensation: Attorney General Sam Mayanja assured affected families that they will receive full, timely compensation before being required to vacate their properties.
• Construction & Transfer Halts: Local leaders in Nansana Municipality and Gombe Division have already halted new construction within the designated radius, and technical officers have suspended land transfers in the zone.
Expanding Local Vaccine and Oncology Production
Founded by Ugandan scientist Dr. Matthias Magoola, Dei BioPharma currently operates on 400 acres and requires the additional 600 acres to construct specialized production lines, including dedicated oncology facilities and Active Pharmaceutical Ingredient (API) units.
The expansion is a critical step toward meeting the stringent requirements of international bodies like the US Food and Drug Administration (FDA) and major donor-funded procurement programs. Notably, Dei BioPharma was recently confirmed as a registered manufacturer on the Africa CDC pooled procurement platform for a five-year period beginning September 1, 2026.
The Matugga manufacturing hub works in tandem with the company's pharmaceutical-grade starch and industrial sugar processing plant in Namasagali, Kamuli District, positioning Uganda as an emerging player in continental biological medicine and vaccine security.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0